Journal Club 2026

Next HOPA Journal Club

Tuesday, March 17, 2026 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Orange button that says click here to register

The moderator for March's Journal Club session is:

Jeremy Pappacena, PharmD, BCOP, Allegheny Health Network Cancer Institute, Pittsburgh, PA

March's Journal Club presenters include:

Anna Wszeborowska, PharmD

PGY2 Oncology Pharmacy Resident

Hospital of the University of Pennsylvania, Philadelphia, PA

Article:

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Zachary Zawacki, PharmD

PGY2 Oncology Pharmacy Resident

Munson Medical Center, Traverse City, MI

Article:

Ianalumab plus Eltrombopag in Immune Thrombocytopenia

Featured Articles

Collaborations

Pharmacy Students and Oncology Pharmacists Combat Cancer Misinformation with National Initiative

February 24, 2026

The Hematology/Oncology Pharmacy Association (HOPA) is proud to team up with the Student National Pharmaceutical Association (SNPhA) for the Cancer Clarity Challenge, a new national competition.

An image of the Capitol building on a cloudless day

Advocacy

Congress Passes Health Extenders and PBM Reform

February 09, 2026

Here's what HOPA members should know about the end of the recent government shutdown, the resulting appropriations bills passed by Congress, and what the package includes pertaining to health care.

A doctor's hands holding an image of lungs

HOPA News

Late-Breaking HOPA News: NeoADAURA: Advancing Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

January 26, 2026

Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP, breaks down the results from the NeoADAURA trial and what its findings may mean for neoadjuvant osimertinib's role in the treatment of resectable EGFR-mutated NSCLC.